<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Moens, H.J.</title>
    <link>http://repub.eur.nl/res/aut/3280/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Antibiotic prophylaxis for haematogenous bacterial arthritis in patients with joint disease: a cost effectiveness analysis (Article)</title>
      <link>http://repub.eur.nl/res/pub/9612/</link>
      <pubDate>2001-01-01T00:00:00Z</pubDate>
      <description>OBJECTIVE: To assess the cost effectiveness of antibiotic prophylaxis for
          haematogenous bacterial arthritis in patients with joint disease. METHODS:
          In a decision analysis, data from a prospective study on bacterial
          arthritis in 4907 patients with joint disease were combined with
          literature data to assess risks and benefits of antibiotic prophylaxis.
          Effectiveness and cost effectiveness calculations were performed on
          antibiotic prophylaxis for various patient groups. Grouping was based on
          (a) type of event leading to transient bacteraemia-that is, infections
          (dermal, respiratory/urinary tract) and invasive medical procedures-and
          (b) the patient's susceptibility to bacterial arthritis which was
          increased in the presence of rheumatoid arthritis, large joint prostheses,
          comorbidity, and old age. RESULTS: Of the patients with joint disease, 59%
          had no characteristics that increased susceptibility to bacterial
          arthritis, and 31% had one. For dermal infections, the effectiveness of
          antibiotic prophylaxis was maximally 35 quality adjusted life days (QALDs)
          and the cost effectiveness maximally $52 000 per quality adjusted life
          year (QALY). For other infections, the effectiveness of prophylaxis was
          lower and the cost effectiveness higher. Prophylaxis for invasive medical
          procedures seemed to be acceptable only in patients with high
          susceptibility: 1 QALD at a cost of $1300/QALY; however, the results were
          influenced substantially when the level of efficacy of the prophylaxis or
          cost of prophylactic antibiotics was changed. CONCLUSION: Prophylaxis
          seems to be indicated only for dermal infections, and for infections of
          the urinary and respiratory tract in patients with increased
          susceptibility to bacterial arthritis. Prophylaxis for invasive medical
          procedures, such as dental treatment, may only be indicated for patients
          with joint disease who are highly susceptible.</description>
    </item>
  </channel>
</rss>